表紙
市場調査レポート

腸炎:パイプライン製品の分析

Enterocolitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 293885
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
腸炎:パイプライン製品の分析 Enterocolitis - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 43 Pages
概要

腸炎とは大腸および小腸の炎症のことを指します。主な症状には、発熱や腹部膨満、吐き気、下痢、直腸出血、倦怠感などがあります。腸炎の要因として、腸内組織の炎症や、胃内容排出の遅滞、腹壁部の紅斑症、無呼吸発作、化膿症、心血管虚脱などが挙げられます。主な治療法には抗生物質などが含まれています。

当レポートでは、世界各国での腸炎(全腸炎、小腸結腸炎)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

腸炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

腸炎:企業で開発中の治療薬

腸炎:大学/機関で研究中の治療薬

腸炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

腸炎:企業で開発中の製品

腸炎:大学/機関で研究中の製品

腸炎の治療薬開発に従事している企業

  • Angothera GmbH
  • AvidBiotics Corp.
  • Infant Bacterial Therapeutics AB
  • Sigma-Tau Pharmaceuticals, Inc

腸炎:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

腸炎:最近のパイプライン動向

腸炎:休止中のプロジェクト

腸炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7920IDB

Summary

Global Markets Direct's, 'Enterocolitis - Pipeline Review, H1 2016', provides an overview of the Enterocolitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Enterocolitis
  • The report reviews pipeline therapeutics for Enterocolitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Enterocolitis therapeutics and enlists all their major and minor projects
  • The report assesses Enterocolitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Enterocolitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Enterocolitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Enterocolitis Overview
  • Therapeutics Development
    • Pipeline Products for Enterocolitis - Overview
    • Pipeline Products for Enterocolitis - Comparative Analysis
  • Enterocolitis - Therapeutics under Development by Companies
  • Enterocolitis - Therapeutics under Investigation by Universities/Institutes
  • Enterocolitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Enterocolitis - Products under Development by Companies
  • Enterocolitis - Products under Investigation by Universities/Institutes
  • Enterocolitis - Companies Involved in Therapeutics Development
    • Angothera GmbH
    • AvidBiotics Corp.
    • Infant Bacterial Therapeutics AB
    • Sigma-Tau Pharmaceuticals, Inc
  • Enterocolitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies for Enterocolitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AvR2-V10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C-34 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IBP-9414 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NRG-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Necrotizing Enterocolitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STP-206 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Enterocolitis - Recent Pipeline Updates
  • Enterocolitis - Dormant Projects
  • Enterocolitis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2015: Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis
      • Feb 04, 2014: Sigma-Tau Pharmaceuticals Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants
      • Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Enterocolitis, H1 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Enterocolitis - Pipeline by Angothera GmbH, H1 2016
  • Enterocolitis - Pipeline by AvidBiotics Corp., H1 2016
  • Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H1 2016
  • Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Enterocolitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Enterocolitis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Enterocolitis, H1 2016
  • Number of Products under Development for Enterocolitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top